Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
STTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $11.76
Previous CloseN/A
Volume43.14K
Average Volume (3M)240.44K
Market Cap
$40.13M
Enterprise Value-$8.06M
Total Cash (Recent Filing)$57.39M
Total Debt (Recent Filing)$3.41M
Price to Earnings (P/E)―
Beta2.95
Next Earnings
May 07, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding47,899,240
10 Day Avg. Volume146,794
30 Day Avg. Volume240,439
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.90
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.41
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$4.00Price Target Upside376.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Investor InterestKey Phase 1 milestones for SL-325 are expected to spur investor interest, marking the first clinical data following the company's strategic pivot.
Market OpportunityShattuck's pivot into the inflammatory bowel disease market is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.
Preclinical DataEncouraging IND-enabling data for SL-325 indicates a clean safety profile and favorable dosing, which aligns with approved therapies.
Bears Say
Financial PerformanceShattuck posted a full-year EPS of ($1.49), which was below consensus estimates.
Pipeline StageAnalyst maintains a Hold Rating given the early stage of the company pipeline at this time and a lack of near-term value drivers.
---
Ownership Overview
19.04% Insiders
7.10% Mutual Funds
0.22% Other Institutional Investors
65.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.69 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $40.13M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Mar 27, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.319 by -$0.051.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Undervalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.28.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,899,240 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.319. Following the earnings report the stock price went down -3.39%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (376.19% Upside)
$4.00 (376.19% Upside)
Blogger Sentiment
Neutral
STTK Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.54%
12-Months-Change
Fundamentals
Return on Equity
-67.23%
Trailing 12-Months
Asset Growth
-42.19%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
---
STTK Stock 12 Month Forecast
Average Price Target
$4.00
▲(376.19% Upside)
Technical Analysis
CytomX Therapeutics
―
Precision BioSciences
―
Kronos Bio
―
Gain Therapeutics
―
PepGen Inc.
―
Best Analysts Covering STTK
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-56.33%
reiterated a buy rating last month
Copying Marc Frahm's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -56.33% per trade.
---